Cannabis News

Technical advances in cannabis curing focus on water activity and terpene stability

Published

5 months ago

January 18, 2026

admin

Curing is one of those phases of cannabis production that almost everyone agrees is important, but that importance hardly translates into cannabis facilities. It’s understandable that growers want to maximize their canopy space first and foremost. After all, more flowers, more income. However, the irony is that by the time a plant reaches the curing room, most of the money has already been spent. The genetics are locked in, the lights have done their job, the rooms have been marked, the harvest has been carefully handled. And yet, quality is often validated or left behind.

Simon Knobel of Calyx Containers has spent an amazing amount of time thinking about this disintegration. The company started about 9 years ago, when Simon and his co-founder Alex were still in school and adult cannabis was becoming legal in Massachusetts. “Back then, cannabis packaging meant pill bottles, borrowed wholesale from the pharmaceutical world and reused without much thought,” explains Simon. “Our initial instinct wasn’t to do something revolutionary. It was just to build something that made sense for cannabis.”

As the company developed a range of packaging formats, the focus was on quality at the point of sale. “Scent retention, ease of use, shelf life, that was the pace of our design process. What took longer to fully register was that the degradation didn’t just happen after packaging. In many cases, it was already baked in during curing.”

Simon and Calyx did extensive market research to understand what was happening with quality degradation. “It’s good to talk not only with operators, but with consumers.” A story stuck. Simon recalls interviewing a client who was on a ski trip with his family and trying to hide the fact that he had cannabis with him. This awkwardness of smell, discretion and manipulation became a design problem. The sliding cover, integrated gasket, meant the elimination of the twisting motion that gave some users a literal pain in the wrist. But it also opened up a deeper line of research.

As Calyx began to talk more seriously with growers, a recurring question came up. Where exactly does quality start to slip? To answer this, the company partnered with the Cannabis Research Coalition and worked with Dr. Allison Justice on research based on the cure. “What we found was that it wasn’t particularly comfortable for anyone relying on legacy methods,” says Simon. “One of the biggest drivers of terpene preservation was the stability of water activity. When water activity drops below 0.55 aW, the stomata begin to collapse, then shrink, then break. At that point, the mono-terpenes escape.”

These mono-terpenes are responsible for most of the aromas associated with quality cannabis. “They are also volatile in nature. Once they’re gone, they’re gone,” highlighted Simon.

Basic methods and alternatives
Traditional healing methods are based on burping. Opening containers, exchanging air, manually regulating humidity. “This methodology works, but it also introduces oxygen. In addition, the plant material is also subject to mechanical stress. Both oxygen and mechanical stress accelerate degradation, thus hampering quality.”

Calyx Cure was designed as an alternative to that ritual. “Instead of active intervention, Calyx Cure uses a passive atmospheric film with selective permeation properties. The layers are designed to allow specific gases to move through the material while others are restricted. Biological curing processes continue, but without opening the container, without introducing excess oxygen and without handling the flower.”

In controlled studies, Calyx saw a 33% improvement in monoterpene profile preservation compared to traditional approaches such as turkey pouches. “Practically speaking, that first hit of aroma you get when you open a jar, driven largely by monoterpenes, is intact.”

Complicating the picture is that curing is not reversible. There is a persistent belief that if cannabis dries out too much, there are no moisture packs or other interventions that can bring it back. “Excessive drying slows down the enzymatic reactions, alters the aging process and permanently changes the composition of the terpenes. Once the quality is lost at that stage, the bottle cannot revive it,” he said.

Curing and speed to market
Therefore, post-harvest processes cannot be the last element of cannabis facility design. “Sometimes speed or short-term cost savings drive the decision. Cure less, move product faster and assume the container will handle the rest.” Market dynamics don’t help either. When a new market opens and the shelves are empty, speed is rewarded and cutting corners can be the difference between hitting dispensaries later.

Calyx approaches it as a manufacturing and engineering problem rather than a branding exercise. Unlike much of the packaging industry, which operates largely as a middleman, Calyx operates its own factory in Utah. “That vertical integration allows us to iterate quickly. New designs can be prototyped in 1 or 2 weeks.”

This can be a huge plus, as quality control is a hot topic in the wider world of agriculture, not just cannabis. The industry often talks about wanting nutraceutical or food standards. These industries have already solved the complexity of the supply chain. They know how to produce in one region and deliver consistently to another. Cannabis, especially if it wants to move globally, will need similar discipline.”

And as with food packaging, sustainability is part of that equation in cannabis. Calyx has extensively studied compostable and hemp-based structures. “Compostable materials struggle with terpene conservation and water activity control. If the package breathes too much, the plant pays the price.”

Instead, Calyx’s approach to sustainability is based on reducing the use of materials at the manufacturing level. “The cover molded joint is a good example,” explains Simon. “Traditional seals require cutting circular inserts from large sheets, creating huge waste. We’ve designed molds where a small amount of polymer forms the cover and joint in one plane, creating almost zero waste and a fully recyclable component.”

Healing, it seems, is not passive waiting. “It’s an active and fragile process,” says Simon. “And like most fragile things in cannabis, it benefits from being engineered rather than inherited.”

For more information:
Calyx vessels
1991 W Parkway Blvd. West Valley City, UT, 84119-2026
724-303-7481
(email protected)
calyxcontainers.com

Related Topics:activity advances Cannabis curing focus stability Technical Terpene water

Up Next

Hemp Farmers And Patients Who Rely On CBD Need More Than Just A Delay In The Looming Federal Ban (Op-Ed)

Don't Miss

Michigan Lawmakers Weigh Bill To Create Statewide Cannabis Reference Lab To Standardize Testing

Cannabis News

Entourage Health, formerly WeedMD, enters creditor protection

Published

50 minutes ago

June 30, 2026

admin

Entourage Health Corp. has entered creditor protection. The company and six related entities filed on June 17 under the Companies’ Creditors’ Arrangement Act owed approximately $240.1 million to the sole affiliate of the LiUNA Pension Fund, its owner, its secured creditor and the lender that is now funding the money (First Report pp. 3-6-9

That affiliate, 2437653 Ontario Inc. No. 1 company, Entourage, secured a 2024 deal that took the former WeedMD private and off the TSX Venture Exchange (December 2024 PR). Shareholders were paid half a Canadian cent per share, or C$0.005, and the board recommended a sale in December 2024 (December 2024 PR).

Jason Alexander, head of the special committee of independent directors, recommended to shareholders. “The transaction ensures that shareholders will receive immediate tangible value while positioning the Company for future growth and flexibility,” Alexander said (December 2024 PR). The company took on $167.6 million in debt in that sale, having already breached the covenant with the same guarantee (December 2024 PR). Eighteen months later that debt was $240.1 million when it was filed, and the growth promised by the sale is a settlement (First Report 6-18 p.

Adult use is off, medical is still running
The leisure business is closing, not saving. Entourage laid off about 53 workers in early June before the order, and 22 remain (First Report p. 6 Adult use inventory is being cleared, finished products are shipped to provincial distributors, and flowers are sold in bulk to the market to other licensed growers (First Report p. 12 Color Cannabis, Dime Bag and Saturday Cannabis are the brands going down with it (First Report p. 5

What remains open is the doctor’s arm as the exclusive supplier of cannabis under the Starseed brand to local residents of the Workers International Union of North America (First Report p. 5 The pension fund that funds the procedure is tied to the same union that the medical brand serves, and the part of Entourage that serves union members is the part that is kept alive while the rest is sold for parts.

At the end of July the money runs out with no new money (First Report p. 11 The money comes again from the pension fund affiliate, a $1.1 million debtor-in-possession facility at 5% per annum, no commitment fee, no exit fee (First Report pp. 10-11). The monitor, Ernst & Young, checked terms against other DIP loans in the cannabis sector from January 2024 and concluded that a third-party lender would not lend on better terms given the state of the business (First Report p. 11 The lender, which already owed $240 million, is the only one willing to advance another million to keep the lights on through the sale.

Health Canada is the largest unsecured creditor, owed $494,505, ahead of all suppliers and competitors on the company’s books (List of Creditors p. 1 Supreme Cannabis is owed $262,133, medical platform HelloMD is owed $169,564, the Town of Aylmer is owed $144,815, the Independent Retail Cannabis Board is owed $137,098 and High Tide is owed $124,583 (List of Creditors p. 1 Unsecured claims total $3,288,333 in more than 100 names, many of which have yet-to-be-determined amounts by medical clinics (List of Creditors 1-5 p. Against $240 million guaranteed, none of them will see much.

In the June 29 return, the lender asks the judge to extend the stay until August 28, approve the DIP facility, and double the Administrative and Directors fees to $500,000 each (First Report 4-8-12. p. The directorship is rising as directors face payroll, holiday pay and excise duties over a longer period of time, and the company’s directors and officers insurance expires at the start of July (First Report p. 12

The sales process starts on the same day, based on a marketing effort that started around May and was presented before the deal that sparked interest but no one could make a deal (First Report p. 13 Insiders and affiliates have until July 6th to say they intend to bid, the bid deadline is July 30th, the successful bid must be received by August 7th, and the outside deadline is August 28th (First Report p. 15 The affiliate of the pension fund has written to the Monitor that it will not make an offer (First Report p. 16), and any other affiliate that does so must be removed from the process (First Report p. 16 The settlement request for non-cannabis equipment and the sale of the Aylmer facility, a 26,000-square-foot extraction and processing facility that has been the company’s production base at 250 Elm St.

the source

For more information:
Neighborhood Health
1.844.933.3636
(email protected)
entouragehealthcorp.com

Cannabis News

DEA And FDA Highlight How Marijuana Is Safer Than Alcohol And Opioids During Rescheduling Hearing’s Opening Day

Published

57 minutes ago

June 30, 2026

admin

Attorneys for the Drug Enforcement Administration (DEA) on Monday highlighted testimony about the medical benefits of marijuana and its relative safety compared to other substances such as alcohol and opioids in the opening day of a hearing. The Trump administration’s cannabis rescheduling proposal.

Marijuana Moment spoke with several people in the audience for Monday’s hearing to find out how the testimony is going, despite the proceedings not being broadcast live to the public at the request of one congressman and others.

According to those sources, DEA attorney James J Schwartz stated that the government is the proponent of the proposed rule to formally move cannabis from Schedule I to Schedule III of the Controlled Substances Act (CSA), stating that the hearing is “not about the recreational use of marijuana” and “about regulation, not about legalization.”

“The government has presented no evidence to suggest that marijuana is not dangerous. All controlled substances are dangerous,
he said “However, controlled substances must be evaluated against the risks they pose, balanced against the medical benefits they provide.”

Dominic Chiapperino, director of the Food and Drug Administration’s Center for Controlled Drug Evaluation and Research and one of two DEA witnesses, testified about how federal health officials formed their recommendation to reschedule cannabis.

Opponents of the reform have used a new two-part test that they argue is a bad departure from a previous analysis, although a DEA lawyer said the hearing is not about that issue, and Chiapperino said the new test is now considered “every time” a new analysis is done on a drug.

The FDA official said the agency compared marijuana to alcohol, opioids and other substances in its scheduling analysis, and found that marijuana’s daily harms were lower than all or most of those comparators.

Cannabis is associated with fewer overdose deaths than comparable substances, Chiapperino said, and when reports of cases involving deaths mention marijuana, the deaths are often attributed to secondary incidents such as accidents or self-inflicted harm. Marijuana’s potential for overdose deaths is “much lower” than other Schedule I drugs and Schedule II drugs. Rather than opioids, the FDA official said.

As for withdrawal in regular users, Chiapperino testified that cannabis has symptoms similar to tobacco, including irritability, but alcohol has “more of a withdrawal syndrome,” which can include seizure and death.

Also on Monday, the lawyers of some of the parties against the reorganization had the opportunity to cross Chiapperino.

Kevin Sabet, president and CEO of the prohibitionist organization Smart Approaches to Marijuana, who was also invited to attend the hearing, said in a video posted on social media that it is “surreal” to see the government arguing that cannabis’s medical uses and relatively minor harms are “just lying through their teeth.”

The DEA “is in a very awkward position to argue the opposite of what it’s been arguing for the last 50 years, the opposite of what the science says, the opposite of what the evidence is,” he said, “which is, of course, to argue against the government that marijuana is more harmful than we thought, not less harmful.”

In short, the government has so far been repeating the inappropriate comparison of marijuana to alcohol, heroin, and other opioids. And duplicating the unprecedented new two-part test for medical use now accepted, which overturns a century of work in this medical…

— Smart Approaches to Marijuana (@learnaboutsam) June 29, 2026

On Tuesday, opponents of the review will have an opportunity to cross-examine the FDA official, and the government’s second witness, Corey Burchman, a doctor from New Hampshire, will begin his testimony. The DEA announced in a filing last week that it will do so Testify on “How Medical Marijuana Provides Medical Benefit to Pain Patients.”

On Monday, a DEA attorney said Burchman would “describe the real-world impacts of treating pain with marijuana instead of opioids” based on his experience with both and discuss how he has “personally transitioned patients from opioids to marijuana for their pain.”

The witness will also testify about the differences between cannabis and opioids in terms of withdrawal and overdose, he said.

Before the hearing began, marijuana reform activists rallied They held a press conference outside DEA headquarters to highlight how they feel of the process – criticizing the fact that supporters of the reform were not invited to participate and that the proceedings are not reproduced live, despite the “transparency” oath of the officials.

DEA Administrator Terrance Cole only organizations and individuals opposed to marijuana reform have been invited to the hearing as a designated participant – telling followers that they do not meet the definition of “interested person” to participate because they are not “affected or prejudiced by any rule or proposed rule that may be issued.”

last week, Marihuana Moments sent petitions to DEA Chief Administrative Law Judge Derek Julius and DEA Administrator Cole asking for them reverse the decision to ban the public from tuning into the cannabis hearing via live stream. A Congressmen and other journalists later joined that request.

—
Marijuana Moment’s journalism is made possible by readers like you, who value this work enough to support us Patreon Monthly Pledges. If you rely on our reports to stay informed of important developments in cannabis, please help us do this becoming a permanent subscriber today.

Backed by us at the $25/month level, you’ll have access to our Bill Tracker so you don’t miss any important marijuana legislation in your state.
—

The opponents who are participating in the hearing submitted statements last week anticipate the anti-marijuana arguments they intend to make during the procedure.

The hearing it will end before July 15.

Acting Attorney General Todd Blanche in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA).

According to a separate order signed by the acting attorney general, the upcoming hearing will include Class III marijuana.

Preliminary hearing process on the marijuana redistricting process initiated by the Biden administration It was halted last year amid allegations of improper communications and witness selection.

the current The marijuana redistricting process is being challenged in several ways which have been upheld by a federal Court of Appeals. those pieces of State attorneys general have filed lawsuits against cannabis reform, Opponents of marijuana legalization and a a cannabis-based biopharmaceutical corporation.

Meanwhile, the reorganization of state-licensed medical cannabis is already having a major impact.

The Congressional Research Service published a report on the current rescheduling of cannabis Certified patients with medical marijuana from state licensed dispensaries are now eligible for Class III. “The order appears to allow end users to use marijuana medically without a CSA prescription,” he says.

The Bureau of Alcohol, Tobacco, Firearms and Explosives (ATF) has published a Draft update to a gun purchase form to recognize the legal status of medical marijuana in the reprogramming. The revised section of the question states that only the “recreational use or possession of marijuana” is federally prohibited, omitting the prior form’s mention of medical cannabis.

The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

Even the DEA, which has long opposed cannabis legalization and accused the Biden administration of stalling the initiative in the reorganization process, has done so. It launched a registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.

The Department of Transport, on the other hand, issued guidelines stating this use Legal medical cannabis in the state is still no excuse for truck drivers to test positive for drugspilots and other safety-sensitive personnel.

A congressional committee recently Federal officials voted to block further steps to reschedule cannabishowever lawmakers from both parties told Marihuana Moment they don’t think that provision will be enacted become law

user photo Carlos Gracia.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

cbdMD welcomes White House call for fair treatment of hemp-derived products

Published

1 day ago

June 29, 2026

admin

cbdMD welcomes the Administration’s call for Congress to ensure fair treatment of hemp-derived products under federal law and calls for immediate action to revise hemp regulations to ensure fair treatment of hemp products under federal law.

In a letter to congressional leadership this week, the White House Office of Management and Budget identified hemp reform as a priority strongly supported by the Administration. The petition calls on Congress to ensure fair treatment of hemp-derived products by maintaining access to appropriate full-spectrum CBD products, and by maintaining Congress’ intent to reduce products that pose health risks. The administration also urged Congress to pass a responsible federal framework or at least extend the current implementation period to give lawmakers time to get policy right. The request builds on the president’s previous public statements urging lawmakers to protect access to full-spectrum CBD products that millions of Americans rely on.

“We are encouraged to see the administration so clearly championing the responsible, scientific hemp products that consumers depend on every day,” said Ronan Kennedy, CEO of cbdMD. “cbdMD has always believed that the future of this category is built on quality, transparency, and clear rules that separate them from bad actors. A federal framework that protects consumer access, promotes safety, and provides certainty to companies that provide certainty is what this industry and the people it serves deserve. We applaud the policymakers who are working to achieve this outcome.”

“We believe CbdMD is purpose-built for this next phase of the market,” added Kennedy. “Our focus remains on serving our customers with reliable and effective products, supporting responsible regulation and building long-term value for our shareholders as the category continues to evolve. Along the way, we will continue to evaluate the opportunities this evolving environment holds.”

For more information:
cbdMD
cbdmd.com/